Ocugen Licenses Gene Therapy OCU400 in Middle East and North Africa Deal Worth Up to $259M
Biotechnology company Ocugen, Inc. (NASDAQ:OCGN) has granted Roots Pharmaceutical and partner Al-Dhow International Holding exclusive rights to commercialize OCU400, its therapy for Retinitis Pigmentosa, across the Middle East and North Africa. Under the deal, Ocugen stands to collect as much as $4 million in initial licensing and development fees, alongside future revenue-based payments that could reach $255 million. Ocugen will also earn a 22% royalty on regional sales and will serve as the sole producer of commercial doses under an accompanying supply contract.
The partnership expands the market for OCU400 into a territory where Retinitis Pigmentosa, an inherited condition causing gradual vision loss, occurs at rates estimated to be 10 to 20 times higher than in North America or Europe. Roots Pharmaceutical will handle regional operations, leveraging its existing distribution network across Gulf and North African health systems to connect patients with the treatment.
Market attention now turns to ongoing clinical trials for OCU400. Ocugen expects main data from its Phase 3 liMeliGhT study during early 2027, after which it plans to file for marketing approval with health regulators in the United States and Europe. Ocugen stock fell 6.52% to $0.8854 on the news.
Key points
- Ocugen, Inc. (NASDAQ:OCGN) inked an exclusive territorial license for its OCU400 gene therapy with Roots Pharmaceutical.
- Financial terms include up to $4 million up front and in early milestones, $255 million in commercial targets, and 22% royalties.
- The target disease, Retinitis Pigmentosa, occurs 10 to 20 times more frequently in MENA than in the U.S. or European Union.
- Ocugen will handle all commercial manufacturing of OCU400 under an associated supply arrangement.
- Key Phase 3 trial results for OCU400 are scheduled for release during the first quarter of 2027.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What are the details of Ocugen's licensing deal with Roots Pharmaceutical?
Ocugen granted exclusive MENA rights for OCU400 to Roots Pharmaceutical in exchange for up to $4 million in upfront and early development milestones, up to $255 million in sales milestones, and a 22% royalty on net sales.
What disease does OCU400 target?
OCU400 treats Retinitis Pigmentosa, a genetic eye disorder that leads to progressive loss of sight and potential blindness.
When will clinical trial results for OCU400 be reported?
Topline results from Ocugen's Phase 3 liMeliGhT trial are anticipated in the first quarter of 2027, preceding planned regulatory filings in the U.S. and Europe.